Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07368660 · ClinicalTrials.gov registry record · NA
InPART RX - Epicenters
A NA study of Hospital Infection and Standardized Antibiotic Prescribing Ratio (SAR), sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 169
- Enrollment target
- 4
- Study locations
NCT07368660: Completed NA study of Hospital Infection and Standardized Antibiotic Prescribing Ratio (SAR), sponsored by Emory University.
NCT07368660 is a NA study of Hospital Infection and Standardized Antibiotic Prescribing Ratio (SAR) that has completed, run by Emory University. The registered enrollment target is 169 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07368660, a NA study of Hospital Infection and Standardized Antibiotic Prescribing Ratio (SAR), has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 169 participants
- Enrollment target
- 4
- Study locations
Study Summary
InPART Rx is a collaborative research study to measure the impact of a planned quality improvement initiative to reduce unnecessary antibiotic prescribing by the Hospital Medicine Service through a process of receiving peer-comparison summary prescribing data bimonthly. The initiative is a collaboration between EHC Pharmacy, the School of Medicine (SOM) Division of Infectious Diseases, and the SOM Hospital Medicine Service. Roughly one-third of antibiotics prescribed in the hospital setting are for the wrong dose, wrong drug, or wrong duration, resulting in considerable unnecessary antibiotic exposure among the inpatient population. Such use increases patient risk for adverse events such as infectious diarrhea or antibiotic-resistant infections. Inpatients cared for by Hospital Medicine providers are a growing proportion of all patients, and developing efficient techniques to reduce unnecessary antibiotic prescribing by these providers would benefit this growing population of patients. The research team aims to measure the impact of implementing a process to provide peer comparisons of antibiotic prescribing among Hospitalists at four Emory Healthcare (EHC) hospitals back to these providers in an effort to minimize unnecessary antibiotic prescribing. All 147 current Hospital Medicine Service providers will participate as part of the Division's quality improvement effort, receiving no compensation. Only summary patient encounter information without private health insurance (PHI) will be presented back to the providers; investigators will track changes in summary prescribing metrics and summary patient outcomes every month. If such an automated peer-comparison feedback process is effective in safely reducing unnecessary antibiotic prescriptions in EHC, similar processes may be adapted to other inpatient provider groups or serve as a model for other healthcare systems. The goal of this quality improvement (QI) work is to use traditional QI methods of peer-comparison
Primary Outcome
The observed provider-specific antibiotic prescribing rate is defined as the billed days of therapy (DOT) of Broad-Spectrum, Hospital-Onset (BS-HO) antibiotics per 1000 billed patient-days.
Conditions Studied
Interventions
- OTHER Usual Care
- OTHER Messaging Hospitalists
Study Locations (4)
Georgia
- Emory Saint Joseph's Hospital - Atlanta
- Emory University Hospital Midtown (EUHM) - Atlanta
- Emory University Hospital (EUH) - Atlanta
- Emory Johns Creek Hospital - Johns Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2024-12-31 |
| Phase | NA |
What the finished NCT07368660 record still lists
NCT07368660 is an interventional study that assigns participants to a tested intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Hospital Infection appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT07368660 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT07368660 about?
NCT07368660 is a clinical study titled "InPART RX - Epicenters". InPART Rx is a collaborative research study to measure the impact of a planned quality improvement initiative to reduce unnecessary antibiotic prescribing by the Hospital Medicine Service through a process of receiving peer-comparison summary prescribing data bimonthly. The initiative is a collabora...
What is the current status of trial NCT07368660?
This trial is currently completed. It is a NA study. The enrollment target is 169 participants. The study started on 2023-01-01. Estimated completion is 2024-12-31.
What conditions does trial NCT07368660 study?
This clinical trial studies the following conditions: Hospital Infection, Standardized Antibiotic Prescribing Ratio (SAR).
What interventions are being tested in trial NCT07368660?
The interventions under investigation include: Usual Care (OTHER), Messaging Hospitalists (OTHER).
Who is sponsoring clinical trial NCT07368660?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07368660 being conducted?
This trial has 4 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07368660's enrollment target sits among peer trials
169 619th of 2000 higher than 1,382 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI